Abstract
Type II thyroplasty (TPII) is one of the surgical options offered in the management of adductor spasmodic dysphonia (AdSD); however, there have been no detailed reports of its safety and associated complications during the perioperative period. Our aim was to assess the complications and safety of TPII. TPII was performed for consecutive 15 patients with AdSD from April 2012 through May 2014. We examined retrospectively the perioperative complications, the degree of surgical invasion, and recovery process from surgery. All patients underwent successful surgery under only local anesthesia. Vocal fold erythema was observed in 14 patients and vocal fold edema in 10 patients; however, all of them showed complete resolution within 1 month. No patient experienced severe complications such as acute airway distress or hemorrhage. Fourteen patients were able to have oral from the 1st postoperative morning, with the remaining patient able to have oral intake from the 2nd postoperative day. In addition, no patient experienced aspiration postoperatively. In conclusion, only minor complications were observed in association with TPII in this study. No dysphagia was observed postoperatively, which is an advantage over other treatments. The results of our study suggest that TPII is a safe surgical treatment for AdSD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Zwirner P, Murry T, Swenson M, Woodson GE (2005) Acoustic changes in spasmodic dysphonia after botulinum toxin injection. J Voice 5:78–84
Edgar JD, Spanienza CM, Bidus K, Ludlow CL (2001) Acoustic measures of symptoms in abductor spasmodic dysphonia. J Voice 15:362–372
Miller RH, Woodson GE, Jankovic J (1987) Botulinum toxin injection of the vocal fold for spasmodic dysphonia. A preliminary report. Arch Otolaryngol Head Neck Surg 113:603–605
Dedo HH (1976) Recurrent laryngeal nerve section for spastic dysphonia. Ann Otol Rhinol Laryngol 85:451–459
Aronson AE, De Santo LW (1983) Adductor spastic dysphonia: three years after recurrent laryngeal nerve resection. Laryngoscope 93:1–8
Netterville JL, Stone RE, Rainey C, Zealear DL, Ossoff RH (1991) Recurrent laryngeal nerve avulsion for treatment of spastic dysphonia. Ann Otol Rhinol Laryngol 100:10–14
Berke GS, Blackwell KE, Gerratt BR, Verneil A, Jackson KS, Sercarz JA (1999) Selective laryngeal adductor denervation-reinnervation: a new surgical treatment for adductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 108:227–231
Genack SH, Woo P, Colton RH, Goyette D (1993) Partial thyroarytenoid myectomy: an animal study investigating a proposed new treatment for adductor spasmodic dysphonia. Otolaryngol Head Neck Surg 108:256–264
Isshiki N, Tsuji DH, Yamamoto Y, Iizuka Y (2000) Midline lateralization thyroplasty for adductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 109:187–193
Chan SW, Baxter M, Oates J, Yorston A (2004) Long-term results of type II thyroplasty for adductor spasmodic dysphonia. Laryngoscope 114:1604–1608
Isshiki N, Yamamoto I, Fukagai S (2004) Type 2 thyroplasty for spasmodic dysphonia: fixation using a titanium bridge. Acta Otolaryngol 124:309–312
Sanuki T, Yumoto E, Minoda R, Kodama N (2010) Effects of type II thyroplasty on adductor spasmodic dysphonia. Otolaryngol Head Neck Surg 142:540–546
Sanuki T, Yumoto E, Kodama N, Minoda R, Kumai Y (2014) Long-term voice handicap index after type II thyroplasty using titanium bridges for adductor spasmodic dysphonia. Auris Nasus Larynx 41:285–289
Isshiki N, Sanuki T (2010) Surgical tips for type II thyroplasty for adductor spasmodic dysphonia: modified technique after reviewing unsatisfactory cases. Acta Otolaryngol 130:275–280
Salassa JR (1999) A functional outcome swallowing scale for staging oropharyngeal dysphagia. Dig Dis 17:230–234
Rosen CA, Lee AS, Osborne J, Zullo T, Murry T (2004) Development and validation of the voice handicap index-10. Laryngoscope 114:1549–1556
Novakovic D, Waters HH, D’Elia JB, Blitzer A (2011) Botulinum toxin treatment of adductor spasmodic dysphonia: longitudinal functional outcomes. Laryngoscope 121:606–612
Holzer SE, Ludlow CL (1996) The swallowing side effects of botulinum toxin type A injection in spasmodic dysphonia. Laryngoscope 106:86–92
Nomoto M, Tokashiki R, Hiramatsu H, Konomi U, Motohashi R, Sakurai E, Toyomura F, Ueda Y, Inoue S, Tsukahara K, Suzuki M (2015) The comparison of thyroarytenoid muscle myectomy and type II thyroplasty for spasmodic dysphonia. J Voice 29:501–506
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Mizoguchi, K., Hatakeyama, H., Yanagida, S. et al. Perioperative complications and safety of type II thyroplasty (TPII) for adductor spasmodic dysphonia. Eur Arch Otorhinolaryngol 274, 2215–2223 (2017). https://doi.org/10.1007/s00405-017-4463-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00405-017-4463-5